
A phase 3 randomized trial of two hormone therapies showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.

A phase 3 randomized trial of two hormone therapies showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.

Women receiving a supportive care drug to reduce bone loss caused by breast cancer treatment may actually be getting more than that—improved survival and lower risk of metastatic recurrence.


























